Lynparza (olaparib)

January 14, 2020February 21, 2020

FDA Reviewing Lynparza-bevacizumab as First-line Maintenance for Advanced Ovarian Cancer, Regardless of BRCA Status

News

The U.S. Food and Drug Administration (FDA) has agreed to review AstraZeneca and Merck‘s request to extend the indication of oral Lynparza (olaparib) as a first-line maintenance therapy in combination with ... Read more

October 30, 2019October 30, 2019

Lynparza-Avastin First-Line Maintenance Therapy Delays Cancer Progression in Advanced OC, Phase 3 Study Shows

News

Adding Lynparza (olaparib) to Avastin (bevacizumab) as a first-line maintenance treatment significantly delayed disease progression in women with advanced ovarian cancer — regardless of BRCA mutation status — interim data from a Phase ... Read more

January 7, 2019

BRACAnalysis CDx Approved in US as Companion Diagnostic Test for First-line Lynparza Treatment

News

Myriad Genetics‘ BRACAnalysis CDx has been approved by the U.S. Food and Drug Administration as a companion diagnostic test to identify women with ovarian cancer eligible for first-line maintenance treatment with Lynparza (olaparib). ... Read more

October 24, 2018

Lynparza Maintenance Delays Progression in Ovarian Cancer Patients by 3 Years, Phase 3 Trial Shows

News

Ovarian cancer patients with BRCA mutations who received Lynparza (olaparib) maintenance treatment after first-line platinum-based chemotherapy lived three years longer without signs of disease worsening than patients who received a ... Read more

May 14, 2018

Researchers Discover Mutations Behind Resistance to PARP Inhibitors Like Lynparza

News

Scientists have found mutations in the poly ADP-ribose polymerase (PARP) gene that cause resistance to PARP inhibitor therapies — such as Lynparza (olaparib) — in a mouse model and in one ... Read more

May 11, 2018

Lynparza Tablets Approved in EU to Treat Advanced, Platinum-sensitive Ovarian Cancers

News

The European Medicines Agency (EMA) has approved Lynparza (olaparib) tablets as a maintenance therapy for ovarian cancer patient who have relapsed, but have had a complete or partial response to platinum-based chemotherapy, and ... Read more

March 21, 2018

Genetic Testing Helps Identify Ovarian Cancer Patients with BRCA Mutations, UK Study Finds

News

Genetic testing as part of routine cancer care, an approach called mainstreamed genetic testing, or MGT, is a feasible way to test BRCA mutations in ovarian cancer patients, a new U.K. study ... Read more

September 1, 2017

Lynparza Maintenance Reduces Risk of Disease Progression in Advanced Ovarian Cancer Patients, SOLO-2 Trial Shows

News

Women with BRCA-mutated relapsed ovarian cancer whose tumors responded to platinum-based chemotherapy took significantly longer to see their disease progressing when given AstraZeneca’s Lynparza (olaparib) as a maintenance therapy, compared to placebo. In addition to ... Read more

June 7, 2017June 7, 2017

Lynparza Prolongs Progression-Free Survival, Sustains Quality of Life in Women with BRCA-Mutated Relapsed Ovarian Cancer

News

Women with BRCA-mutated relapsed serous ovarian cancer who received AstraZeneca’s Lynparza (olaparib) as a maintenance therapy after responding to platinum-based chemotherapy took an average 14 months to see their disease progress, compared to 7.3 ... Read more

March 20, 2017March 20, 2017

Inhibiting DNA Repair Enzyme Called PARG Could Be Way to Fight Ovarian Cancer

News

Inhibiting the PARG enzyme could be a good way to fight ovarian cancer, according to a study. The research, “First-In-Class Chemical Probes Against Poly(ADP-Ribose) Glycohydrolase (PARG) Inhibit DNA Repair With ... Read more